Insight

Nov 12, 2024, 19:34

5 papers about Lung Cancer suggested by Stephen Liu

Stephen Liu, Head of Developmental Therapeutics at Georgetown Lombardi Comprehensive Cancer Center, shared a few must-reads papers on X:

Phase II randomized study of maintenance atezolizumab (A) versus atezolizumab + talazoparib (AT) in patients with SLFN11 positive extensive stage small cell lung cancer. S1929

Authors: Nagla Abdel Karim et al.

Stephen Liu

Afatinib and Necitumumab in EGFR-Mutant Non-Small Cell Lung Cancer with Acquired Resistance to EGFR Tyrosine Kinase Inhibitors

Authors: Nathaniel J. Myalla, Jennifer G. Whisenant, Joel W. Neal, Wade T. Iams, Karen L. Reckamp, Sally York, Lynne D. Berry, Yu Shyr, Leora Horn, Heather A. Wakelee, Sukhmani K. Padda

Stephen Liu

The Phase 3 KEYLYNK-006 Study of Pembrolizumab plus Olaparib versus Pembrolizumab plus Pemetrexed as Maintenance Therapy for Metastatic Nonsquamous Non–Small-Cell Lung Cancer

Authors: Jhanelle E. Gray et al.

Stephen Liu

Durvalumab Versus Chemotherapy as First-line Treatment for Metastatic NSCLC With Tumor PD-L1 Expression ≥25%: Results from the Randomized Phase 3 PEARL Study

Authors: Shun Lu et al.

Stephen Liu

Safety, Efficacy, and Biomarker Analysis of Crizotinib in MET-Mutated Non–Small Cell Lung Cancer—Results from the Drug Rediscovery Protocol

Authors: Karlijn Verkerk et al.

Stephen Liu

Follow Stephen Liu on X for more such content.

Stephen V Liu is an Associate Professor of Medicine at Georgetown University, where he holds the positions of Director of Thoracic Oncology and Head of Developmental Therapeutics at the Georgetown Lombardi Comprehensive Cancer Center. As a board-certified medical oncologist specializing in lung cancer and drug development, Dr. Liu is known for his expertise in advanced thoracic malignancies.

His research focuses on novel therapeutic agents and innovative combinations to improve treatment outcomes for patients with lung cancer. Dr. Liu has received multiple teaching awards and actively engages in post-graduate education initiatives. Furthermore, he co-hosts the official podcast of the International Association for the Study of Lung Cancer (IASLC), “Lung Cancer Considered”.

Adrian Langlebeni Adrianus J de Langen Andrei Ungureanu Ann Hoeben Anne M.L. Jansen Arnold Pilz Atul Kumar Berber Piet Bin Zhao Birgit S. Geurts Bo Zhu Bryan A. Faller cancer Carl M. Gay Daniel R. Carrizosa Dariusz Kowalski Dongqing Lv Edem S. Agamah Egbert F. Smit Emile E. Voest Flavia De Angelis Gerarda J.M. Herder Gijs F. de Wit Hans Gelderblom Heather A. Wakelee Helen Mann Henk M.W. Verheul Himani Aggarwal Ilse A.C. Spiekman James Chih-Hsin Yang Jennifer G. Whisenant Jhanelle E. Gray Jieling Miao Joel W. Neal John Schallenkamp Karen Kelly Karen L. Reckamp Karlijn Verkerk Kathan Mehta Kejun Nan Konstantin Laktionov Krishna C. Alluri Lauren A. Byers Laurien J. Zeverijn Leora Horn Lin Wu Liyan Jiang Lizza E. L. Hendriks Lung cancer Lynne D. Berry Mark Shamoun Mary W. Redman Mehmet Ali Nahit Şendur Michael Schenker Michel M. van den Heuvel Milena Perez Mak Minghao Song Nagla Abdel Karim Nathaniel J. Myalla Ngoc van Tran NSCLC OncoDaily Oncology Paul Roepman Qiming Wang Rajini K. Malisetti Rashida Orlova Rui Ma Sally York Samer S. Kasbari Sayed M.S. Hashemi Shun Lu Stephen Clarke Sukhmani K. Padda Tae Min Kim Terufumi Kato Tijmen J.W.T. van der Wel Viktoriya Leonova Vincent van der Noort Wade T. Iams Wei-Lien Wang William J. Petty Xiaojin Shim Yi-Long Wu Ying-Qi Zhao Yinglei Liu Yu Shyr Zachary Zimmer Ziping Wang

New Paper Alert! HR+ Breast Cancer: Efficacy of Subsequent Treatments After CDK4/6 Inhibitor Progression

Gemma Peters: Heading into 2025 with hope

Carlos Rodriguez-Galindo: The Man Who Will Cure the World

Esophageal Cancer: Symptoms, Causes, Stages, Diagnosis & Treatment

Faster, Flexible and Affordable: Mikhail Groubman on Building a Global Legacy in Clinical Research in an Untapped Market

Special Coverage